Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 1999

View Archived Issues

Synsorb signs letter of agreement to acquire cancer biotech company

Australian patent issued for oral form of paclitaxel

FDA grants priority review to Boehringer Ingelheim's new stroke therapy

New U.S. patent protects Molecular Biosystems' microsphere technology

ReQuip effective in restless legs syndrome

Positive efficacy and safety results support clinical testing of ViaStem

KV Pharmaceutical and Pfizer sign licensing agreement for oral delivery system

Cerus cleared by FDA to begin clinical trials of transplantation system

Medarex joins forces with Danish investors to develop human antibody therapeutics

Praxis purchases intellectual property allowing development of antirejection drug

Glaxo Wellcome seeks approval for Zyban in the E.U.

Luxiq granted marketing clearance by the FDA

Licensing opportunity from the NIH: antiinflammatory cytokine

Cytokine production inhibitors prepared and tested at Ortho-McNeil

Novel vaccine technology available for licensing from BTG

New lantibiotic isolated and characterized by U. of Maryland group

Roche obtains European marketing approval for transplant drug

New heterocyclic compounds from Searle preferentially inhibit iNOS

Mediolanum's AChE inhibitor falls by the wayside

Dual 5-HT reuptake inhibitors/5-HT1A antagonists patented by Lundbeck

Platelet aggregation inhibitors in development at SmithKline Beecham

Pfizer claims new, improved compositions of alatrofloxacin

AC-2993 advances to clinical trials in type II diabetes

Novartis obtains first western approval for new antimalarial drug combination

Lilly's recombinant glucagon now being launched, will replace animal-derived product

Second-generation tetracyclines afford significant neuroprotection in stroke model

NMDA receptor antagonists potentiate opioid-induced analgesia in animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.